#309 Omnipod and Dexcom Updates

Horizon System

The Omnipod Horizon system is designed to cater to a wide range of users, from those struggling with diabetes management to "super users" aiming for precise control. Bret Christensen explains that the system's flexibility allows users to set personalized targets and make insulin dosing decisions every five minutes, enhancing control over blood glucose levels 1. This adaptability is complemented by features like hypo protect mode, which adjusts insulin delivery during specific situations like exercise or sleepovers 1.

Horizon is getting a value from the CGM, from Dexcom every five minutes. And then it's making an insulin dosing decision every five minutes.

--- Bret Christensen

The system is expected to be available by the end of 2020, with plans to expand its user base significantly in 2021. Christensen highlights the importance of preparing for market access, supply, and product support to ensure a smooth rollout 2.

   

Algorithmic Pumping

Algorithmic insulin pumping represents a significant advancement in diabetes management, offering automated insulin delivery that could transform patient outcomes. Scott Benner emphasizes the importance of proper support and settings for these systems, as incorrect parameters can lead to suboptimal results 3. The goal is to simplify the process for users, potentially eliminating the need for manual parameter adjustments as algorithms improve and insulin becomes faster acting 3.

The goal will be one day to eliminate parameters, right.

--- Bret Christensen

Christensen acknowledges the challenge of managing patient expectations, as many anticipate a "set it and forget it" system, which is not yet feasible. However, he remains optimistic about the future of algorithm-based insulin delivery as a standard in diabetes care 3.

   

Interoperability

Interoperability in diabetes technology is crucial for enhancing patient choice and system efficiency. Scott Benner discusses how Dexcom's continuous glucose monitor (CGM) data can be integrated with various insulin pumps to create closed-loop systems that automate insulin delivery 4. This integration allows patients to select their preferred sensors, such as Dexcom G6, G7, or Abbott Libre 2, enhancing flexibility and personalization in diabetes management 5.

The information coming from the Dexcom continuous glucose monitor is going to help pump companies to build their own algorithms.

--- Scott Benner

The collaboration between Dexcom and Omnipod exemplifies this trend, aiming to streamline the pathway to market and improve user experience by offering a range of compatible devices 5.